India's Drug Controller General of India (DCGI) has cut drug approval timelines by more than 50%, with clinical trial approvals now processed in 120, 135 days and marketing authorizations granted in under 150 days, according to Economic Times data for calendar year 2025. DCGI Rajeev Singh Raghuvanshi confirmed that no application exceeded the 150-day mark during the period, a marked departure from prior norms that made India a slower regulatory destination relative to peers. The regulator has also eliminated the requirement for prior approval at the pre-clinical stage, reducing friction at the earliest phase of drug development where speed materially affects R&D investment decisions. For pharmaceutical companies operating in or entering India, the compressed timeline directly improves capital efficiency on pipeline assets and reduces the regulatory risk premium that has historically made India less attractive for early-stage clinical work. Watch whether faster approvals translate into measurable increases in clinical trial filings and foreign sponsor participation over the next two to four quarters.
India's Expenditure Finance Committee has cleared a Rs 1.25 lakh crore outlay for India Semiconductor Mission 2.0, up 64 percent from ISM 1.0's Rs 76,000 crore. The proposal now goes to the Cabinet, as two chip plants begin commercial output and a third, CG Semi, is set to open July 4, 2026.
The Supreme Court blocked Trump from firing Federal Reserve board member Lisa Cook, preserving the Fed's independence from presidential removal power. A separate ruling the same day gave Trump broader authority to dismiss leaders of other independent federal agencies.
The US Supreme Court has blocked President Trump's attempt to fire Federal Reserve governor Lisa Cook, who faced unproven mortgage fraud allegations. The ruling preserves Fed independence for now and keeps a politically charged removal case alive in the courts.
The US Supreme Court, splitting along ideological lines, has allowed the Trump administration to end Temporary Protected Status for Haitian and Syrian immigrants.
